Comparison · NCT00985725-sae
Lisdexamfetamine Dimesylate (LDX) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lisdexamfetamine Dimesylate (LDX) vs Placebo: serious adverse events. Trial comparisons, record NCT00985725-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00985725-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0282 | 0.00776 | 0.097 | wilson | |
| Risk in group 2 | 0.0556 | 0.0218 | 0.134 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0274 | -0.109 | 0.0493 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.507 | 0.0959 | 2.68 | log | |
| Odds ratio, group 1 over group 2 | 0.493 | 0.0873 | 2.78 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Lisdexamfetamine Dimesylate (LDX) than on Placebo | 36.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | 2 | 71 | EG000 |
| Group 2 | Placebo | Administered orally once-daily for 9 weeks. | 4 | 72 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
- NCT number
- NCT00985725
- Phases
- PHASE2
- Conditions
- Major Depressive Disorder
- Interventions
- SPD489 (Lisdexamfetamine dimesylate), Matching placebo
- Lead sponsor
- Shire
- Results first posted
- 2012-04-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00985725?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00985725-sae